New insights on the regulation of INK4/ARF locus expression

The INK4/ARF locus encodes the key tumor suppressors, p15INK4b, p16INK4a and ARF, that together regulate the pRb and p53 major tumor suppressive networks. Given the importance of the products of the INK4/ARF locus in tumor suppression, transcription from the locus is tightly governed. Over the last decade, intense study to elucidate the regulation of this locus exposed that the genes encoded in the INK4/ARF locus are controlled both independently as well as in a coordinated manner. A known regulatory site responsible for the coordinated silencing of all three genes in the INK/ARF locus is positioned in close proximity to the p15INK4b gene called Regulatory Domain (RD). Interaction of the CDC6 protein with the RD triggers recruitment of histone deacetylases, which increase methylation of histone H3 on lysine 9 (H3K9) and in turn cause heterochromatinization of the p15INK4b, p16INK4a and ARF promoters leading to their silencing. In this context, we recently reported that the E3 ubiquitin ligase and transcription cofactor E6AP (also known as UBE3A) acts as a positive regulator of the INK4/ARF locus [1]. Mechanistically, we demonstrated that E6AP inhibits CDC6 expression by interacting with E2F1 and reducing its ability to bind to the CDC6 promoter and induce its transactivation (Figure 1). Importantly, this novel regulatory pathway is clinically relevant in non-small cell lung cancer (NSCLC), since we showed that patients with the E6AP-low/CDC6-high/ p16INK4a-low expression endure the worst overall survival. This correlation predicts the prognostic value of this expression signature. A key finding from our work is that the ability of E6AP to modulate E2F1 transcriptional activity is not limited to the CDC6 gene, as we demonstrated that the levels of other E2F1 gene targets were also altered in E6AP-deficient cells. In accord with these findings, we recently published an independent report showing that in prostate cancer cells, E6AP reduces the ability of E2F1 to bind to p27 promoter and to induce its transcription [2]. A particularly intriguing regulator of the expression of the tumour suppressors encoded in the INK4/ARF locus is the long non-coding RNA (lncRNA) ANRIL (antisense non-coding RNA in the INK4 locus). ANRIL gene is transcribed in the antisense orientation relative to the INK4/ARF gene cluster. ANRIL promotes the epigenetic repression of its neighbor tumor suppressors in the INK4/ ARF locus by physically interacting with the Polycomb proteins Suz12 and Cbx7, which in turn recruit the Polycomb repressive complex 1 and 2 to the locus, leading to histone modification and silencing of the locus [3]. The contribution of ANRIL to cancer development has attracted much attention in recent years, and ANRIL oncogenic role is now solidly established in a variety of carcinomas. This is the case for NSCLC, where multiple recent papers convincingly demonstrate that high ANRIL levels correlate with poor prognosis (i.e. [4]). In this context however, very little is known about the mechanisms of ANRIL regulation. The only hints come from two independent groups that reported that ANRIL is transcriptionally activated by E2F1 [5, 6]. This finding, together with our recently published data showing that E6AP regulates the expression of the INK4/ARF locus, and that E6AP modulates E2F1 transcription activity, prompt us to speculate that E6AP could maintain expression levels of the tumor suppressor genes in the INK4/ARF locus by inhibiting ANRIL in an E2F1-dependent manner. We propose a model wherein E6AP promotes activation of the INK4/ARF locus by repressing the expression of the two key negative regulators of the locus, CDC6 and ANRIL. Further studies will be required to establish the relevance of the E6AP/E2F1/ANRIL/ p16INK4a axis in NSCLC, as well as in other cancers. Nevertheless, we believe this opens potential new therapeutic options in the light of the recent interest that therapeutics based on lncRNAs targeting are attracting in the context of cancer [7]. Editorial